The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers

Neurology

Volumn 78, Issue 11, 2012, Pages 781-786

  Inzelberg, R ^a,c   Cohen, O S ^a,c   Aharon Peretz, J ^d,f   Schlesinger, I ^d,f   Gershoni Baruch, R ^e,f   Djaldetti, R ^c,g   Nitsan, Z ^a   Ephraty, L ^a   Tunkel, O ^a   Kozlova, E ^a   Inzelberg, L ^a,c   Kaplan, N ^a,c   Fixler Mehr, T ^b,c   Mory, A ^e   Dagan, E ^e,h   Schechtman, E ⁱ   Friedman, E ^b,c   Hassin Baer, S ^a,c  

^a Sagol Neuroscience Center   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d Department of Neurology   (Israel)

^e RAMBAM MEDICAL CENTER   (Israel)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g RABIN MEDICAL CENTER   (Israel)

^h UNIVERSITY OF HAIFA   (Israel)

ⁱ BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEVODOPA; ANTIPARKINSON AGENT; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ETHNICITY; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; AGED; ARTICLE; ETHNIC GROUP; GENETIC PREDISPOSITION; GENETICS; JEW; MIDDLE AGED; MUTATION; NEOPLASM; ONSET AGE; PHYSIOLOGY; SEX DIFFERENCE; STATISTICAL MODEL; SURVIVAL;

AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; JEWS; LEVODOPA; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84859929853     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318249f673     Document Type: Article

References (31)

1. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007; 69:1542-1550. (Pubitemid 47537862)
2. D'Amelio M, Ragonese P, Sconzo G, Aridon P, Savettieri G. Parkinson's disease and cancer: Insights for pathogenesis from epidemiology. Ann NY Acad Sci 2009;1155:324-334.
3. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: A systematic review and meta-analysis. Cancer Causes Control 2010;21:697-707.
4. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer patterns in patients with Parkinson's disease. Br J Cancer 2005;92: 201-205. (Pubitemid 40188456)
5. Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder. Neurology 2007;69:2093-2104. (Pubitemid 350175712)
6. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51:296-301. (Pubitemid 34206285)
7. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607. (Pubitemid 39531225)
8. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425. (Pubitemid 43145083)
9. Tomiyama H, Li Y, Funayama M, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 2006;12: 1102-1108. (Pubitemid 44336593)
10. Hassin-Baer S, Laitman Y, Azizi E, et al. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation: Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol 2009; 256:483-487.
11. Jannson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985;17:505-509. (Pubitemid 15019991)
12. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in Parkinson's disease. BMJ 1995;310:1500-1501.
13. Inzelberg R, Israeli-Korn SD. The particular relationship between Parkinson's disease and malignancy: A focus on skin cancers. J Neural Transm 2009;116:1503-1507.
14. Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S. Treatment with levodopa and risk for malignant melanoma. Mov Disord 2007;22:1252-1257. (Pubitemid 47325031)
15. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease. Cancer Causes Control 2007;18:705-711. (Pubitemid 46988238)
16. Inzelberg R, Rabey JM, Melamed E, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. J Neural Transm 2011;118:1199-1207.
17. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Cancer risk in association with Parkinson disease: A population-based study. Parkinsonism Relat Disord 2010; 16:186-190.
18. Saunders-Pullman R, Barrett MJ, Stanley KM, et al. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson's disease. Mov Disord 2010;25:2536-2545.
19. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer in Parkinson's disease. J Neurol 2000;247:429-434.
20. Strongosky AJ, Farrer M, Wszolek ZK. Are Parkinson disease patients protected from some but not all cancers? Neurology 2008;71:1650-1651.
21. Ye J, Pavlicek A, Lunney EA, Rejto PA, Teng CH. Statistical method on nonrandom clustering with application to somatic mutations in cancer. BMC Bioinformatics 2010; 11:11.
22. Forbes SA, Bhamra G, Bamford S, et al. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet 2008;10:10.
23. Berthier A, Navarro S, Jiménez-Sáinz J, et al. PINK1 displays tissue-specific subcellular location and regulates apoptosis and cell growth in breast cancer cells. Hum Pathol 2011;42:75-87.
24. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446:153-158. (Pubitemid 46398669)
25. Deng H, Le W, Guo Y, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci 2006;251:102-106. (Pubitemid 44792149)
26. Garber K. Parkinson's disease and cancer: The unexplored connection. J Natl Cancer Inst 2010;102:371-374.
27. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600. (Pubitemid 39531224)
28. Lin X, Parisiadou L, Gu X-L, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology Induced by Parkinson's-disease- related mutant alpha synuclein. Neuron 2009;64:807-827.
29. Greggio E, Zambrano I, Kaganovick A, et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimmer that undergoes intramolecular autophosphorylation. J Biol Chem 2008;283:16906-16914.
30. Smith WW, Pei Z, Jiang H, et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006;9:1231-1233. (Pubitemid 44454261)
31. Anand VS, Braithwaite SP. LRRK2 in Parkinson's disease: Biochemical functions. FEBS J 2009;276:6428-6435